Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder Clear all
Completed Not applicable Interventional

Physical Therapy Trial for Pelvic Pain

NCT00434343
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome, Chronic Prostatitis, Chronic Pelvic Pain Syndrome
Interventions
Global Therapeutic Massage (GTM), Myofascial physical therapy (MPT)
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Chicago, Illinois • Maywood, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation

NCT04074616
View directory record Official record
Conditions
Chronic Spinal Cord Injury, Neurogenic Bladder
Interventions
High Dose, Low dose
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

NCT01476800
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of YM178
Interventions
YM178 OCAS, Ketoconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 25, 2026, 2:56 AM EDT
Recruiting No phase listed Observational

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

NCT04235764
View directory record Official record
Conditions
Bladder Cancer
Interventions
modified resectoscope, TURBT
Device · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional

Transcutaneous Tibial Nerve Stimulation (TTNS) Treatment in Spina Bifida Pediatric Patients With Neurogenic Bladder

NCT06025734
View directory record Official record
Conditions
Spina Bifida
Interventions
Transcutaneous Tibial Nerve Stimulation (TTNS) treatment
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional Results available

The Personal Patient Profile Decision Support for Patients With Bladder Cancer

NCT05033067
View directory record Official record
Conditions
Bladder Cancer
Interventions
P3BC
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

NCT00880334
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Cancer
Interventions
Docetaxel, vandetanib, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 25, 2026, 2:56 AM EDT
Withdrawn No phase listed Observational

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

NCT01060319
View directory record Official record
Conditions
Bladder Cancer, Skin Cancers, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

NCT02951767
View directory record Official record
Conditions
Bladder Cancer
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 25, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

NCT07322263
View directory record Official record
Conditions
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)
Interventions
Intravesical Gemcitabine and Docetaxel
Drug
Lead sponsor
Michael A. O'Donnell
Other
Eligibility
18 Years to 99 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Completed No phase listed Observational

Markers of Response to Intravesical Bladder Cancer Therapy

NCT01007058
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional

Internet-based System for Cancer Patients to Self-report Toxicity

NCT00578006
View directory record Official record
Conditions
Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
Interventions
Questioners, STAR website
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 4 Interventional

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

NCT00224146
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence, Quality of Life
Interventions
oxybutynin transdermal delivery system (Oxytrol(r))
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
Mobile, Alabama • Tucson, Arizona • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer

NCT02722538
View directory record Official record
Conditions
Urinary Bladder Cancer
Interventions
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
Drug
Lead sponsor
Taris Biomedical LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 2 Interventional Results available

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

NCT01282463
View directory record Official record
Conditions
Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
Interventions
Docetaxel, Ramucirumab DP, Icrucumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 25, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

NCT06733363
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Carcinoma, Recurrent Bladder Carcinoma, Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 1 Bladder Cancer AJCC v8
Interventions
Behavioral Dietary Intervention, Telephone- Based Intervention
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Overactive Bladder Telemedicine Non-inferiority Trial

NCT05117918
View directory record Official record
Conditions
Overactive Bladder
Interventions
SUFU Clinical Care Pathway for Overactive Bladder, Telemedicine
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 25, 2026, 2:56 AM EDT
Terminated Not applicable Interventional Results available

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

NCT00147238
View directory record Official record
Conditions
Bladder Cancer, Genitourinary Cancer, Prostate Cancer
Interventions
Ferumoxtran-10 (USPIO), MR lymphangiography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 25, 2026, 2:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Retropubic Hydrodissection and Trocar-induced Bladder Perforation During Retropubic Midurethral Slings

NCT07208682
View directory record Official record
Conditions
Bladder Perforation, Retropubic Midurethral Sling, Retropubic Hydrodissection
Interventions
retropubic hydrodissection
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

NCT01561352
View directory record Official record
Conditions
Other Haemostasis Disorder, Haemorrhagic Cystitis
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Tolterodine ER
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
22
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 25, 2026, 2:56 AM EDT
Withdrawn Not applicable Interventional

Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer

NCT02688348
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 25, 2026, 2:56 AM EDT
Completed Early Phase 1 Interventional Results available

High Frequency SARS for Neurogenic Bladder and Bowel Emptying

NCT05214378
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Finetech-Brindley Sacral Anterior Roots Stimulation System
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Syracuse, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 25, 2026, 2:56 AM EDT
Recruiting Phase 2 Interventional

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

NCT06571708
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Interventions
Gemcitabine, Cisplatin, Cemiplimab, Fianlimab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 25, 2026, 2:56 AM EDT